Work

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Year: 2009

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-009-1083-9

Authors: Paul Haluska, Frank Worden, David Olmos, Donghua Yin, David Schteingart, Gretchen N. Batzel, M. Luisa Paccagnella, Johann S. de Bono, Antonio Gualberto, Gary D. Hammer

Institutions: Mayo Clinic, University of Michigan, Michigan Medicine, Royal Marsden NHS Foundation Trust, Pfizer (United States)

Language: English

Topic: Adrenal and Paraganglionic Tumors

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic

OpenAlex ID: W2065302180

FWCI: 17.53

Cites: 41

Cited by: 197

Related to: 10